Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Total Valuation
Atossa Therapeutics has a market cap or net worth of $109.55M. The enterprise value is $49.24M.
Market Cap$109.55M
Enterprise Value$49.24M
Share Statistics
Atossa Therapeutics has 129,171,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding129,171,420
Owned by Insiders3.41%
Owned by Institutions0.48%
Financial Efficiency
Atossa Therapeutics’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is -38.64%.
Return on Equity (ROE)-0.36
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-38.64%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-1.70M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Atossa Therapeutics is ―. Atossa Therapeutics’s PEG ratio is 0.28.
PE Ratio―
PS Ratio0.00
PB Ratio1.66
Price to Fair Value1.66
Price to FCF-5.65
Price to Operating Cash Flow-3.94
PEG Ratio0.28
Income Statement
In the last 12 months, Atossa Therapeutics had revenue of 0.00 and earned -25.50M in profits. Earnings per share was -0.20.
Revenue0.00
Gross Profit0.00
Operating Income-27.62M
Pretax Income-25.50M
Net Income-25.50M
EBITDA-27.60M
Earnings Per Share (EPS)-0.20
Cash Flow
In the last 12 months, operating cash flow was -26.27M and capital expenditures -16.00K, giving a free cash flow of -26.29M billion.
Operating Cash Flow-26.27M
Free Cash Flow-26.29M
Free Cash Flow per Share-0.20
Dividends & Yields
Atossa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.01
52-Week Price Change-30.33%
50-Day Moving Average0.88
200-Day Moving Average0.82
Relative Strength Index (RSI)56.96
Average Volume (3m)1.16M
Important Dates
Atossa Therapeutics upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Atossa Therapeutics as a current ratio of 14.99, with Debt / Equity ratio of 0.00%
Current Ratio14.99
Quick Ratio14.99
Debt to Market Cap0.00
Net Debt to EBITDA2.79
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Atossa Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Atossa Therapeutics EV to EBITDA ratio is -1.87, with an EV/FCF ratio of -2.27.
EV to Sales0.00
EV to EBITDA-1.87
EV to Free Cash Flow-2.27
EV to Operating Cash Flow-2.27
Balance Sheet
Atossa Therapeutics has $51.84M in cash and marketable securities with $0.00 in debt, giving a net cash position of $51.84M billion.
Cash & Marketable Securities$51.84M
Total Debt$0.00
Net Cash$51.84M
Net Cash Per Share$0.40
Tangible Book Value Per Share$0.57
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Atossa Therapeutics is $6.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.25
Price Target Upside635.29% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-9.42%